-
公开(公告)号：US20100190999A1
公开(公告)日：2010-07-29
申请号：US12359467
申请日：2009-01-26
申请人： Shriprakash Dhar DWIVEDI , Dhimant Jasubhai Patel , Kishor Maneklal Vinchhi , Mahesh Laljibhai Rupapara
发明人： Shriprakash Dhar DWIVEDI , Dhimant Jasubhai Patel , Kishor Maneklal Vinchhi , Mahesh Laljibhai Rupapara
IPC分类号： C07D207/34
CPC分类号： C07D207/34
摘要： The present invention also provides the amorphous form of hemi-calcium salt of atorvastatin with high purity and processes for preparation thereof.
摘要翻译： 本发明还提供了高纯度的阿托伐他汀半钙盐的无定形形式及其制备方法。
-
公开(公告)号：US08115015B2
公开(公告)日：2012-02-14
申请号：US12359467
申请日：2009-01-26
申请人： Shriprakash Dhar Dwivedi , Dhimant Jasubhai Patel , Kishor Maneklal Vinchhi , Mahesh Laljibhai Rupapara
发明人： Shriprakash Dhar Dwivedi , Dhimant Jasubhai Patel , Kishor Maneklal Vinchhi , Mahesh Laljibhai Rupapara
IPC分类号： C07D207/00
CPC分类号： C07D207/34
摘要： The present invention also provides the amorphous form of hemi-calcium salt of atorvastatin with high purity and processes for preparation thereof.
摘要翻译： 本发明还提供了高纯度的阿托伐他汀半钙盐的无定形形式及其制备方法。
-
3.发明授权Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof 失效用于制备HMG CoA还原酶抑制剂的中间体及其制备方法公开(公告)号：US08759518B2
公开(公告)日：2014-06-24
申请号：US13576296
申请日：2011-02-23
IPC分类号： C07D239/02 , C07D405/12 , C07D239/42 , C07D405/06 , C07D257/04
CPC分类号： C07D405/12 , C07D239/42 , C07D257/04 , C07D405/06 , Y02P20/55
摘要： A compound of Formula (1), is disclosed wherein P1 and P2 are alcohol protecting groups or 1,3-diol protecting group, R is selected from: wherein R4a is selected from alkyl, aryl, arylalkyl and cycloalkyl, Rc is selected from H, alkyl, aryl, alkaoxy, haloalkyl, monohaloalkyloxy, and dihaloalkyloxy, Rd is selected from alkyl, aryl, arylalkyl, CF3, halo and NO2 and X is selected from O, N—H, N-alkyl and S, Ra and Rb are same or different and each represents hydrogen, an alkyl group of 1 to 12 carbon atoms, an aryl group of 6 to 12 carbon atoms, or an aralkyl group of 7 to 12 carbon atoms.
摘要翻译： 公开了式（1）的化合物，其中P1和P2是醇保护基或1,3-二醇保护基，R选自：其中R 4a选自烷基，芳基，芳烷基和环烷基，R c选自H 烷基，芳基，烷氧基，卤代烷基，单卤代烷氧基和二卤烷氧基，Rd选自烷基，芳基，芳基烷基，CF 3，卤素和NO 2，X选自O，N-H，N-烷基和S， 相同或不同，各自表示氢，1至12个碳原子的烷基，6至12个碳原子的芳基或7至12个碳原子的芳烷基。
-
4.发明申请INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF 失效制备HMG COA还原酶抑制剂的中间体及其制备方法公开(公告)号：US20130158263A1
公开(公告)日：2013-06-20
申请号：US13576296
申请日：2011-02-23
IPC分类号： C07D405/12 , C07D405/06 , C07D239/42 , C07D257/04
CPC分类号： C07D405/12 , C07D239/42 , C07D257/04 , C07D405/06 , Y02P20/55
摘要： A compound of Formula (1), is disclosed wherein P1 and P2 are alcohol protecting groups or 1,3-diol protecting group, R is selected from: wherein R4a is selected from alkyl, aryl, arylalkyl and cycloalkyl, Rc is selected from H, alkyl, aryl, alkaoxy, haloalkyl, monohaloalkyloxy, and dihaloalkyloxy, Rd is selected from alkyl, aryl, arylalkyl, CF3, halo and NO2 and X is selected from O, N—H, N-alkyl and S, Ra and Rb are same or different and each represents hydrogen, an alkyl group of 1 to 12 carbon atoms, an aryl group of 6 to 12 carbon atoms, or an aralkyl group of 7 to 12 carbon atoms.
摘要翻译： 公开了式（1）的化合物，其中P1和P2是醇保护基或1,3-二醇保护基，R选自：其中R 4a选自烷基，芳基，芳烷基和环烷基，R c选自H 烷基，芳基，烷氧基，卤代烷基，单卤代烷氧基和二卤烷氧基，Rd选自烷基，芳基，芳基烷基，CF 3，卤素和NO 2，X选自O，NH，N-烷基和S，R a和R b相同或 各自表示氢，1〜12个碳原子的烷基，6〜12个碳原子的芳基或7〜12个碳原子的芳烷基。
-
公开(公告)号：US09034901B2
公开(公告)日：2015-05-19
申请号：US13818681
申请日：2011-08-24
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.
摘要翻译： 本发明提供了匹伐他汀及其药学上可接受的盐的制备方法。 特别地，本发明提供了制备水含量小于5％wt / wt的结晶形式的稳定匹伐他汀钙的方法。 本发明还提供基本上不含晶形A的匹伐他汀钙的稳定结晶形式及其用于药物组合物的用途。
-
公开(公告)号：US20140148481A1
公开(公告)日：2014-05-29
申请号：US13818681
申请日：2011-08-24
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.
摘要翻译： 本发明提供了匹伐他汀及其药学上可接受的盐的制备方法。 特别地，本发明提供了制备水含量小于5％wt / wt的结晶形式的稳定匹伐他汀钙的方法。 本发明还提供基本上不含晶形A的匹伐他汀钙的稳定结晶形式及其用于药物组合物的用途。
-
7.发明申请PROCESS FOR MANUFACTURING ROSUVASTATIN POTASSIUM AND CRYSTALLINE AND AMORPHOUS FORMS THEREOF 审中-公开制造萝丝素钾及其晶体和非晶形式的方法公开(公告)号：US20100274014A1
公开(公告)日：2010-10-28
申请号：US12161455
申请日：2007-01-25
IPC分类号： C07D239/42
CPC分类号： C07D239/42
摘要： A process of manufacturing of Rosuvastatin Potassium of formula (I) is disclosed. The process comprises the steps of (a) treating Rosuvastatin protected compound of formula (II) wherein R1 and R2 are same or different having C1-C4 carbon atom or hydrogen or R1 and R2 can combine together to afford a cyclic structure comprising a junction atom as carbon or metal atom such as Si (silicon); with an inorganic base of the kind such as herein described having potassium as cation in a suitable solvent to form Rosuvastatin potassium; (b) isolating Rosuvastatin potassium.
摘要翻译： 公开了制备式（I）的罗苏伐他汀钾的方法。 该方法包括以下步骤：（a）处理罗沙伐他汀保护的式（II）化合物，其中R 1和R 2相同或不同，具有C 1 -C 4碳原子或氢或R 1和R 2可以结合在一起，得到包含连接原子 作为碳或金属原子如Si（硅）; 使用本文所述的无机碱，其在合适的溶剂中具有钾作为阳离子，以形成罗苏伐他汀钾; （b）分离罗苏伐他汀钾。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
